|
1.
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
3.
|
Toschi A, Lee E, Thompson S, et al:
Phospholipase D-mTOR requirement for the Warburg effect in human
cancer cells. Cancer Lett. 299:72–79. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Lee JW, Choi CH, Choi JJ, et al: Altered
MicroRNA expression in cervical carcinomas. Clin Cancer Res.
14:2535–2542. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Liu H, Zhang SZ, Cai SR, Peng JP and Zheng
S: Effect of microRNA143 expression on cell proliferation in
colonic carcinoma. Zhonghua Zhong Liu Za Zhi. 30:498–501. 2008.(in
Chinese).
|
|
6.
|
Guertin DA and Sabatini DM: Defining the
role of mTOR in cancer. Cancer Cell. 12:9–22. 2007. View Article : Google Scholar
|
|
7.
|
Chresta CM, Davies BR, Hickson I, et al:
AZD8055 is a potent, selective, and orally bioavailable
ATP-competitive mammalian target of rapamycin kinase inhibitor with
in vitro and in vivo antitumor activity. Cancer Res. 70:288–298.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Rottiers V and Naar AM: MicroRNAs in
metabolism and metabolic disorders. Nat Rev Mol Cell Biol.
13:239–250. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Osaki M, Takeshita F, Sugimoto Y, et al:
MicroRNA-143 regulates human osteosarcoma metastasis by regulating
matrix metalloprotease-13 expression. Mol Ther. 19:1123–1130. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Kang S, Dong SM, Kim BR, et al:
Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR
pathway in cervical and endometrial cancer cells. Apoptosis.
17:989–997. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Osman A: MicroRNAs in health and disease -
basic science and clinical applications. Clin Lab. 58:393–402.
2012.PubMed/NCBI
|
|
12.
|
Hudson RS, Yi M, Esposito D, et al:
MicroRNA-106b-25 cluster expression is associated with early
disease recurrence and targets caspase-7 and focal adhesion in
human prostate cancer. Oncogene. Sep 17–2012.(Epub ahead of print).
View Article : Google Scholar
|
|
13.
|
Fang R, Xiao T, Fang Z, et al:
MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting
hexokinase 2 gene. J Biol Chem. 287:23227–23235. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Fasolo A and Sessa C: Targeting mTOR
pathways in human malignancies. Curr Pharm Des. 18:2766–2777. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Sheppard K, Kinross KM, Solomon B, Pearson
RB and Phillips WA: Targeting PI3 kinase/Akt/mTOR signaling in
cancer. Crit Rev Oncog. 17:69–95. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Grzybowska-Izydorczyk O and Smolewski P:
mTOR kinase inhibitors as a treatment strategy in hematological
malignancies. Future Med Chem. 4:487–504. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Diaz-Padilla I, Duran I, Clarke BA and Oza
AM: Biologic rationale and clinical activity of mTOR inhibitors in
gyneco-logical cancer. Cancer Treat Rev. 38:767–775. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Barnett CM: Everolimus: targeted therapy
on the horizon for the treatment of breast cancer. Pharmacotherapy.
32:383–396. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Hill EK and Dizon DS: Medical therapy of
endometrial cancer: current status and promising novel treatments.
Drugs. 72:705–713. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Mathupala SP, Ko YH and Pedersen PL:
Hexokinase II: cancer’s double-edged sword acting as both
facilitator and gatekeeper of malignancy when bound to
mitochondria. Oncogene. 25:4777–4786. 2006.
|
|
21.
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: the metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009.PubMed/NCBI
|
|
22.
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Li X, Zhang G, Luo F, et al:
Identification of aberrantly expressed miRNAs in rectal cancer.
Oncol Rep. 28:77–84. 2012.PubMed/NCBI
|
|
24.
|
White NM, Youssef YM, Fendler A, Stephan
C, Jung K and Yousef GM: The miRNA-kallikrein axis of interaction:
a new dimension in the pathogenesis of prostate cancer. Biol Chem.
393:379–389. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Ng EK, Tsang WP, Ng SS, et al:
MicroRNA-143 targets DNA methyltransferases 3A in colorectal
cancer. Br J Cancer. 101:699–706. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Michael MZ, SM OC, van Holst Pellekaan NG,
Young GP and James RJ: Reduced accumulation of specific microRNAs
in colorectal neoplasia. Mol Cancer Res. 1:882–891. 2003.PubMed/NCBI
|
|
27.
|
Jiang S, Zhang LF, Zhang HW, et al: A
novel miR-155/miR-143 cascade controls glycolysis by regulating
hexokinase 2 in breast cancer cells. EMBO J. 31:1985–1998. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Gregersen LH, Jacobsen A, Frankel LB, Wen
J, Krogh A and Lund AH: microRNA-143 down-regulates Hexokinase 2 in
colon cancer cells. BMC Cancer. 12:2322012. View Article : Google Scholar : PubMed/NCBI
|
